2417395-15-2
2417395-15-2
Chemical Structure
Sevasemten
Synonym(s): EDG-5506
- CAS No.: 2417395-15-2
- Formula:C16H11F4N5O2
- Molecular Weight:381.28
IUPAC Name: 2-((5-fluoropyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one
InChIKey: XFPJKQRXBAFXNK-UHFFFAOYSA-N
SMILES: O=C1C=CC(C2=CN=C(OCC(F)(F)F)N=C2)=NN1CC3=CC(F)=CN=C3
Biological Activity: Sevasemten is an orally active, selective allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten decreases muscle damage biomarkers and fibrosis while increasing muscle strength and activity in in Duchenne muscular dystrophy disease models[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sevasemten | 99.32% | Sevasemten is an orally active, selective allosteric inhibitor of skeletal muscle myosin that protects skeletal muscle from contraction-induced injury. Sevasemten decreases muscle damage biomarkers and fibrosis while increasing muscle strength and activity in in Duchenne muscular dystrophy disease models. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russell Alan, et al. Preparation of substituted pyridazinones for use in the treatment of neuromuscular diseases: World Intellectual Property Organization, WO2021231615. 2021-11-18.
- [2]. WHO Drug Information-World Health Organization (WHO).
- [3]. Donovan J, et al. 351P Sevasemten, a fast myosin inhibitor, in adults with Becker muscular dystrophy results in reduced muscle damage biomarkers and functional stabilization[J]. Neuromuscular Disorders, 2024, 43: 104441.682.
- [4]. Russell AJ, et al., Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophy. J Clin Invest. 2023 May 15;133(10):e153837. [Content Brief]
